Results: the results of these studies are indicated as follows: Standard triple therapy with the probiotic Bifidus infantis co-administered for 10 days led to an eradication rate of 90.4%. A lead-in period using the probiotic alone for 14 days followed by the standard triple therapy with the probiotic Bifidus Infantis co-administered for another 10 days, led to an eradication rate of 91.6%. Sequential therapy with the probiotic Bifidus Infantis co-administered for 10 days led to an eradication rate of 92.1%. Lactobacillus Rhamnosus GG yielded a lesser rate of success when used as replacement for Bifidus infantis in the triple therapy

group (79.6% learn more vs 88.4% respectively). Multiple strains probiotic formulas as a single agent (Multilac and Afterbiotic): still ongoing study but interim results of available data indicate a lesser rate of success than Bifidus infantis or Lactobacillus rhamnosus alone (74.3% vs 88.4% respectively). Conclusion: Adding the probiotic Bifidus infantis as an adjuvant to the standard or modified triple, and the sequential or modified sequential therapy led to better

results than the cure rates obtained by the conventional medical therapy (p = 0.001). RAD001 in vitro Bifidus infantis used alone appeared to have a higher potency than Lactobacillus Rhamnosus GG or a multistrain tablet of probiotics in this respect. It is also noteworthy that the probiotics Bifidus infantis, lactobacillus Rhamnosus GG, Multilac, and afterbiotic not only improved the success of eradication but also had led to a significant improvement in the clinical symptoms response after treatment and to a considerable reduction in the incidence of antibiotic associated diarrhea. Key Word(s): 1. Probiotics; 2. Triple therapy; 3. Sequential treatment; 4. H. pylori;

Presenting Author: ADNANM ABU HAMMOUR Additional Authors: ASADIZZIDDIN DAJANI, MOHAMMEDALI EL NOUNOU, MOHAMMEDABDULLAH ZAKARIA Corresponding Author: ADNANM ABU HAMMOUR, ASADIZZIDDIN DAJANI Affiliations: AMC; ADSC; mnc Objective: Over the past decade a worldwide trend of decline in the cure rates of H. pylori is observed. Current eradication rates achieved by the standard triple therapy alone are below 70%. A retrospective survey C-X-C chemokine receptor type 7 (CXCR-7) done 2009 in the UAE revealed a similar experience with reported eradication rates of 69.8%, while earlier eradication rates reported by our group was (95%).This decline in H.Pylori eradication was confirmed by a prospective study that was done in 2011. This decline is believed to be due to the rising clarithromycin and metronidazole resistance caused by the injudicious use of these antibiotics leading to increased activity of the efflux pump of H. pylori, and/or to the emergence of the 23S r-RNA point mutations of the microbe. This led to reduced cure rates by 20–30%.